Table 2.
Diagnostic efficacy of the E7 protein assay versus the HPV test (n/N, %)
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
|---|---|---|---|---|
| CIN2+ | ||||
| E7 protein | 70.6% (48/68) | 67.9% (93/137) | 52.2% (48/92) | 82.3% (93/113) |
| HPV | 86.8% (59/68) | 44.5% (61/137) | 43.7% (59/135) | 87.1% (61/70) |
| E7 protein + HPV | 61.8% (42/68) | 78.1% (107/137) | 58.3% (42/72) | 80.4% (107/133) |
| CIN3+ | ||||
| E7 protein | 67.4% (31/46) | 61.6% (98/159) | 33.7% (31/92) | 86.7% (98/113) |
| HPV | 89.1% (41/46) | 40.9% (65/159) | 30.4% (41/135) | 92.9% (65/70) |
| E7 protein + HPV | 60.9% (28/46) | 72.3% (115/159) | 38.9% (28/72) | 86.5% (115/133) |
Note: CIN2 and CIN3 cases were considered as pathological positive; CIN1, normal, and TCT/Hr-HPV-negative cases were considered as negative, PPV positive predicative value, NPV negative predictive value